Long non-coding RNAs (
LncRNA) play important roles in multiple types of
cancers. We addressed the role of LINC02535 by regulating the miR-30a-5p /
GalNAc Transferase 3 (GALNT3) axis to promote the proliferation, migration, and invasion in
lung adenocarcinoma (LUAD) cells. The
Cancer Genome Atlas (TCGA) database screened differentially expressed lncRNAs. Quantitative real-time PCR analysis (qRT-PCR) confirmed that LINC02535 is highly expressed in LUAD tissues and cells. In vitro experiments showed that LINC02535 promotes the proliferation, migration, and invasion of LUAD cells. A xenograft mouse model was used to show that LINC02535 promotes
tumor growth in vivo.
RNA immunoprecipitation (RIP) and Dual-
luciferase reporter assay results confirmed that LINC02535 targets miR-30a-5p. The
Vicia villosa lectin (VVA) pull-down assay indicated that MUC1 is the glycosylation target of GALNT3, and western blot verified that NF-κB is the downstream signaling pathway of MUC1. We found that LINC02535 was increased in LUAD tissues and cells, and LINC02535 was correlated with the poor prognosis of LUAD patients. miR-30a-5p acts as a
tumor suppressor in LUAD by targeting GALNT3. We also demonstrated that LINC02535 might function as the sponge of miR-30a-5p to up-regulate GALNT3, and consequently promote the proliferation and
metastasis of LUAD. LINC02535 acts as a
competing endogenous RNA (
ceRNA) to interact with miR-30a-5p, thereby upregulating the expression of GALNT3, enhancing the function of MUC1, and activating the NF-κB signaling pathway, promoting the malignant progression of LUAD cells.Abbreviations:
LncRNA:
long non-coding RNA; LUAD:
lung adenocarcinoma; TCGA: The
Cancer Genome Atlas; GALNT3:
GalNAc Transferase 3; qRT-PCR: quantitative real-time PCR analysis; RIP:
RNA immunoprecipitation; SPF: specific pathogen-free; VVA:
Vicia villosa lectin;
ceRNA:
competing endogenous RNA;
MiRNAs:
microRNAs; FBS:
fetal bovine serum; PBS:
Phosphate buffered saline; CCK-8: Cell Counting Kit-8; NSCLC:
non-small cell lung cancer; OC:
ovarian cancer; HCC:
hepatocellular carcinoma.